Published on 23/12/2025
The Rise of Biomarker-Driven Oncology Clinical Trials in China
Introduction
Biomarker-driven oncology trials are transforming cancer treatment by matching therapies to genetic, molecular, and clinical signatures of patients. In China, where cancer incidence is rising sharply, the push toward precision medicine has made biomarker-driven trials a national priority. The National Medical Products Administration (NMPA) has introduced regulatory pathways for companion diagnostics (CDx), next-generation sequencing (NGS), and biomarker validation, while hospitals and CROs are building the infrastructure to conduct complex genomic studies. As part of China’s healthcare modernization, biomarker-based trials not only accelerate drug approvals but also align with global oncology research. This article examines the regulatory framework, operational challenges, and best practices for biomarker-driven oncology clinical trials in China.
Background and Regulatory Framework
China’s Cancer Burden
Cancer is the leading cause of death in China, accounting for nearly 30% of annual mortality. High rates of lung, liver, and gastric cancers have created urgent demand for precision therapies. Biomarker-driven trials are central to improving outcomes and tailoring therapies to Chinese patient populations.
NMPA Guidance on Biomarker Trials
The NMPA has issued guidance on biomarker validation, companion diagnostics, and genetic testing in oncology. Sponsors must submit biomarker assay validation data as part of
Case Example: EGFR Biomarker Trials
EGFR mutations are highly prevalent in Chinese lung cancer patients. Sponsors conducting EGFR-targeted therapy trials in China must validate biomarker assays locally, ensuring accuracy and compliance with NMPA and HGRAC requirements. These trials have accelerated access to life-saving therapies for Chinese patients.
Core Clinical Trial Insights
Biomarker Validation and Companion Diagnostics
Biomarker-driven trials require validated assays and often involve companion diagnostics (CDx). The NMPA mandates that CDx devices undergo simultaneous evaluation with investigational therapies. Sponsors must coordinate drug and diagnostic development to ensure parallel approval.
Infrastructure for Genomic Testing
Tier-1 hospitals in Beijing, Shanghai, and Guangzhou have developed advanced genomic laboratories capable of conducting NGS and biomarker assays. However, Tier-2 hospitals face infrastructure and training gaps, limiting biomarker trial expansion to regional centers.
Patient Recruitment and Diversity
Recruitment for biomarker trials requires pre-screening of patients through genetic testing. Sponsors must collaborate with hospitals to establish genomic screening programs. Ensuring diversity in biomarker-positive populations is critical for generating globally generalizable data.
Data Integration and HGRAC Oversight
Biomarker trials generate sensitive genetic data, requiring HGRAC approval for collection, storage, and export. Data localization laws mandate that genomic data remain in China, complicating multinational integration. Sponsors must establish secure local data systems and harmonize with global trial datasets.
Oncology Areas of Growth
Key areas for biomarker-driven oncology trials in China include lung cancer (EGFR, ALK, ROS1), breast cancer (HER2, BRCA), and immuno-oncology (PD-1/PD-L1). Trials increasingly incorporate multiplex biomarkers, requiring advanced bioinformatics support and complex statistical designs.
Multinational Collaboration
China’s inclusion in global biomarker-driven trials is expanding under ICH E17 MRCT guidance. Harmonizing biomarker assay validation across regions ensures that Chinese data are accepted in FDA and EMA submissions, reducing the need for bridging studies.
Best Practices & Preventive Measures
Sponsors should:
✔️ Engage with NMPA and HGRAC early for biomarker and genomic testing approvals
✔️ Partner with Tier-1 hospitals and genomic laboratories for assay validation
✔️ Use standardized, globally recognized biomarker assays
✔️ Train site staff in biomarker testing and data management
✔️ Ensure data security and compliance with localization laws
✔️ Collaborate with CROs specializing in biomarker-driven trials
These practices reduce regulatory risks and improve trial efficiency.
Scientific & Regulatory Evidence
China’s biomarker framework aligns with ICH E6(R2) GCP, FDA biomarker and CDx guidance, and EMA biomarker validation standards. WHO emphasizes biomarker-driven trials as a cornerstone of precision medicine. NMPA’s parallel drug-diagnostic evaluation reflects international best practices for integrated approvals.
Special Considerations
Rare biomarker populations, such as ROS1-positive lung cancer patients, present recruitment challenges requiring multicenter collaboration. Pediatric oncology biomarker trials require additional ethical safeguards. Sponsors must balance rapid recruitment with ethical and cultural considerations in genetic testing.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek regulatory advice from the NMPA during biomarker assay development and companion diagnostic planning. HGRAC consultations are critical for studies involving genomic data, ensuring compliance with collection and export regulations.
Case Studies
Case Study 1: HER2-Positive Breast Cancer Trial
A sponsor developed a biomarker-driven trial for HER2-positive breast cancer in collaboration with Tier-1 hospitals in Shanghai. By aligning CDx validation with drug development, the sponsor achieved simultaneous approval of both the therapy and diagnostic, accelerating patient access.
Case Study 2: Immuno-Oncology Biomarker Expansion
A PD-L1 biomarker-driven immunotherapy trial recruited over 500 patients across 20 hospitals. With standardized biomarker assays and strong CRO support, the sponsor integrated Chinese data into global submissions accepted by the FDA and EMA.
FAQs
1. What are biomarker-driven oncology trials?
They match therapies to patients based on genetic or molecular markers, improving precision and treatment outcomes in cancer research.
2. What role does the NMPA play in biomarker trials?
The NMPA regulates biomarker validation, companion diagnostic approvals, and ensures compliance with genomic data laws.
3. Why is HGRAC approval needed in biomarker trials?
HGRAC oversees collection, storage, and export of genetic data in China, requiring approvals for genomic testing in clinical trials.
4. What cancers are priorities for biomarker trials in China?
Lung, breast, and immuno-oncology cancers are leading areas, focusing on biomarkers such as EGFR, ALK, HER2, and PD-1/PD-L1.
5. How are biomarker assays validated in China?
Assays must undergo analytical and clinical validation at NMPA-accredited labs, with parallel evaluation of companion diagnostics.
6. Can Chinese biomarker data be used in global submissions?
Yes, if assays are standardized and trials comply with ICH and global requirements, Chinese data can be integrated into FDA/EMA dossiers.
Conclusion & Call-to-Action
Biomarker-driven oncology trials are reshaping cancer treatment in China, supported by NMPA reforms, genomic infrastructure, and global integration. For sponsors, success requires early regulatory engagement, strong hospital partnerships, and compliance with HGRAC and data localization requirements. Organizations conducting oncology trials in China should embrace biomarker-driven strategies to advance precision medicine and deliver life-saving therapies to patients more quickly and effectively.